Bio­gen climbs high­er on Spin­raza sales; inks deal for two new neu­ro­mus­cu­lar drugs

Bio­gen is climb­ing on the Nas­daq Tues­day morn­ing fol­low­ing news that it’s ac­quired two ear­ly-stage drugs for neu­ro­mus­cu­lar dis­or­ders, adding to the com­pa­ny’s pipeline of po­ten­tial pay­outs.

The an­nounce­ment came wrapped in the biotech gi­ant’s sec­ond quar­ter fi­nan­cial state­ments, which al­so not­ed Bio­gen’s Spin­raza sales had climbed to $423 mil­lion in Q2, more than dou­ble the sec­ond quar­ter fig­ure in the same pe­ri­od last year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.